Approximately 65% of American women of reproductive age use some form of contraception, but many may have not found a contraceptive solution that fully meets their needs.1

The American College of Obstetricians and Gynecologists recommends Long-Acting Reversible Contraception (LARC), such as intrauterine devices (IUDs), as a safe and effective contraceptive option for women, including those who have not given birth and adolescents who are sexually active. The use of IUDs in the U.S. has been increasing, yet there has been little product innovation in this category.2-5


Sebela Women’s Health is developing a next-generation IUD platform with products designed to fit the uniqueness of every woman’s body. Developmental features of this IUD platform are a flexible nitinol frame, a preloaded inserter, a smaller insertion tube, and precut retrieval strings. It’s the only platform that will include both a hormonal and hormone-free IUD option—because we understand that women have different needs and preferences. With our innovative portfolio, we seek to offer an improved IUD experience for women and HCPs.


Copper 175 mm2 IUD

Copper 175 mm2 IUD

At a time when demand for hormone-free options is growing rapidly, Sebela is developing the first new hormone-free IUD for the United States market in nearly four decades. Copper 175 mm2 is a lower-dose copper IUD currently in late-stage Phase 3 trials.5,6

Copper 175 mm2 IUD is in Phase 3 clinical research. It is limited by United States Federal Law to investigational use.6

52 mg Levonorgestrel IUD

52 mg Levonorgestrel IUD

We understand that many women who are looking for highly effective pregnancy prevention also appreciate the non-contraceptive benefits afforded by hormone-based contraceptives. That’s why we’re developing an IUD with the advanced design features and benefits of the Sebela platform and a Levonorgestrel reservoir.

52 mg Levonorgestrel IUD is Phase 3 ready. It is limited by United States Federal Law to investigational use.7

Pipeline Products:


1. Daniels K, Abma JC. Current contraceptive status among women aged 15–49: United States, 2015–2017. NCHS Data Brief, no 327. Hyattsville, MD: National Center for Health Statistics. 2018.

2. The American College of Obstetricians and Gynecologists. Clinical. Practice Bulletin. Long-acting reversible contraception: implants and intrauterine devices. 2017:186. Published November 2017. Accessed September 28, 2022. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/11/long-acting-reversible-contraception-implants-and-intrauterine-devices

3. Guttmacher Institute. Contraceptive Use in the United States by Method. Accessed October 7, 2022. https://www.guttmacher.org/fact-sheet/contraceptive-method-use-united-states

4. Nelson AL, Massoudi N. New developments in intrauterine device use: focus on the US. Open Access J Contracept. 2016;7:127-141. doi:10.2147/OAJC.S85755

5. Turok DK, Nelson AL, Dart C, et al. Efficacy, safety, and tolerability of a new low-dose copper and nitinol intrauterine device: phase 2 data to 36 months. Obstet Gynecol. 2020;135(4):840-847. doi: 10.1097/AOG.0000000000003756.

6. ClinicalTrials.gov. Evaluation of the Efficacy, Safety and Tolerability of VeraCept IUD. Updated June 23, 2022. Accessed October 11, 2022. https://clinicaltrials.gov/ct2/show/NCT03633799

7. ClinicalTrials.gov. Evaluation of the Efficacy, Safety, and Tolerability of LevoCept. Updated April 12, 2022. Accessed October 11, 2022. https://clinicaltrials.gov/ct2/show/NCT04457076